Kornimate/medical-research-clean huggingface dataset:
the role of ctdna testing plus ai-based pathology in resectable lscc

Conditions: Lung Squamous Cell Carcinoma

Summary: the goal of this observational study is to explore whether ctdna dynamic monitoring plus ai-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.

this study is a single-center, observational, non-interventional, prospective study. 50 patients diagnosed with lung squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy (ranging 2 to 4 cycles) will be planned to be enrolled in the study. pre-treatment biopsy tissues of enrolled patients will be collected for whole exon sequencing (wes) testing, and personalized detection panel will be customized based on wes testing results. peripheral blood will be collected 1 day before each cycle of neoadjuvant therapy, 1 day before surgery, 3 days after surgery, and 3 weeks after surgery for ctdna testing. in addition, the prediction model of ai-based pathology will be constructed by ai deep learning based on pathological sections of pre-treatment biopsy tissues. all inclued patients will be regularly followed up for at least 5 years.

Eligibility criteria:
inclusion criteria: * histopathology or cytology confirmed the lung squamous cell carcinoma * age ranging from 18 to 75 * agree to participate in this study and sign an informed consent form * treatment-naive tumor * according to the american joint committee on cancer (ajcc) eighth edition of the lung cancer staging manual, the clinical stage is stage ii-iiib resectable or potentially resectable tumor * sufficient tissue/blood samples are available to meet research requirements * the ecog ps score is 0-1 exclusion criteria: * patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form * non-squamous nsclc * unresectable iiia-iiib tumor * patients with solid organ or blood system transplantation * previous use of ctla-4, pd-1, or pd-l1 immune checkpoint inhibitors * patients with interstitial lung disease * patients with acute or chronic infectious disease * pregnant and lactating women * patients who have undergone other clinical drug trials
effect of a liquid toothpaste on periodontal disease

Conditions: Periodontitis; Gingivitis

Summary: the aim of the present clinical study is to evaluate the efficacy and safety of the novel toothpaste in patients diagnosed with gingivitis and/or periodontitis.

the trial was a randomized, double-blind, placebo-controlled, parallel group, single-center(department of periodontology, yonsei university dental hospital) study. 98 patients were assessed for eligibility. since two patients did not meet the inclusion criteria, 96 subjects were randomly assigned to either the test group.the test group was provided a liquid toothpaste and a control group received placebo. at the end of the study, results were analyzed for 87 patients : 42 in the test group and 45 in the control group . the study protocol requested 4 visits- once every two weeks-of each subjects in the center. at the baseline, subjects were randomly allocated to the test group or the control group. scaling and tooth brushing instruction were performed and all of the clinical parameters were evaluated. at the 2- and 4-week examinations, clinical parameters of gi, pi were evaluated and at the 6-week examination, all of the clinical parameters were evaluated. also, microbiological quantitative analysis of this procedure was performed at the baseline and 6-week examinations.

Eligibility criteria:
inclusion criteria: * good general health. * minimum of 20 uncrowned permanent natural teeth (excluding third molars). * initial gingivitis index of 1.1\~2.0 as determined by the use of the loe and silness gingival index. * signed informed consent form. exclusion criteria: * initial plaque index \<1.5, gingival index \<1.0 * smoker * chronic disease (uncontrolled diabetes, liver disease, heart disease, kidney disease..) * subject who had hemorrhagic medical history or who take antiplatelet agent or anticoagulant * subject who need antibiotics for preventive administration * subjects who had preventive treatment or treatment for periodontitis in the last three months * use of orthodontic appliances. * pregnant women or women who are breast feeding. * previous participation in any other clinical trial in the last 30 days * judged unsuitable by investigators for other reasons.
improving sexually transmitted infection (sti) results notification and partner services

Conditions: Sexually Transmitted Infections

Summary: the primary goal of this project is to improve the process for contacting patients that test positive for a sexually transmitted infection (sti) in the emergency department by using text messaging. we believe patients that are contacted by both a phone call and a text message will be reached more often and they will be reached sooner than those that only receive a phone call or only a text message. in addition, patients will be given reminder cards at the time of testing to remind them that they will be contacted within 7 days if they test positive. half of the reminder cards will have a number to call for test results. we believe patients that receive a card with a number are more likely to be contacted within 7 days.

aim 1: to improve the results notification system among all female adolescents who test positive for stis in the ed using mobile phone texting technology. hypothesis 1: we will increase our contact rate for sti positive adolescents in the ed from 65-82%. hypothesis 2: we will decrease the time interval between testing and appropriate sti treatment by the ed. hypothesis 3: we will decrease the recidivism rates for sti positive patients diagnosed in the ed. aim 2: to explore qualitatively the barriers to and preferences for partner notification and treatment among 14-21 year-old females and males being tested for stis in the ed. aim 3: to determine baseline rates of partner notification and preferences around partner notification among sti-positive females in the ed, and to explore the feasibility of ed personnel notifying their sexual partners.

Eligibility criteria:
inclusion criteria: * 14 to 21 years old * seen in the emergency department at cincinnati children's hospital medical center * test positive for an sti exclusion criteria: * seen for a psychiatric evaluation * seen for sexual assault or abuse

Keywords: sti, std
safety, tolerability and pharmacokinetics of liraglutide-depot in healthy subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in healthy subjects.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 20 and 35 kg/m\^2 (both inclusive) with a body weight of at least 60 kg * apart from being obese (bmi above 30 kg/m\^2) the subject has to be considered generally healthy exclusion criteria: * medical history of, or presence of, cancer, diabetes or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine, haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders * clinical or laboratory findings which suggest that the subject cannot be considered generally healthy * prescription medicine and non-prescription medicine with few exceptions * current and prior history of alcohol or drug abuse * current smoking of more than 5 cigarettes per day * mental incapacity, language barriers, or unwillingness to comply with the protocol
laparscopic inguinal hernia repair - does the choice of self-fixated mesh matter?

Conditions: Inguinal Hernia; Surgery

Summary: self-fixed mesh and postoperative pain after laparoscopic inguinal hernia surgery, a randomized clinical trial

pain after inguinal hernia surgery is a major problem for the patient and results in lower quality of life. in this randomized clinical trial we examine if the choice of self-fixed mesh affects post-operative inguinal pain in laparoscopic hernia surgery. 164 patients are randomized and followed up for 1 year.

Eligibility criteria:
inclusion criteria: * patients with a clinical inguinal hernia, who are operated with laparoscopic surgery in day case surgery exclusion criteria: * scrotal or incarcerated hernia * previous laparotomy * asa \>3 * bmi \ 35 * liver cirrhosis * no hernia in clinical examination
ssat 054: non genetic factors in the pathogenesis of ibd in twins

Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis

Summary: this study aims to investigate the role of non-genetic factors in the pathogenesis of inflammatory bowel disease.an exploratory study to investigate differences between the epigenome, microbiota and functional immunology in twins discordant for inflammatory bowel disease.

background: the inflammatory bowel diseases (ibd), crohn's disease (cd) and ulcerative colitis (uc), are debilitating conditions with a complex aetiology. the biggest risk factor for developing ibd is having an affected first degree relative. however when an identical twin is diagnosed with ibd, the other twin goes on to develop the condition in only 20-55% of cases. recent research suggests the microbiota the ecosystem of bacteria within the gut may trigger disease in susceptible individuals. another important research area is the epigenome changes to the structure and regulation of our genome which occur throughout our life. it is known that siblings of crohn's disease sufferers have a changes to the immune system characteristic of crohn';s. however it is not known whether these changes are due to genetic similarity or shared environment. comparison between mono and dizygotic twins elucidates the relative importance of genetic and environmental factors. primary objective: an exploratory study to investigate differences between the epigenome, microbiota and functional immunology in twins discordant for inflammatory bowel disease. study design: multicentre basic science study involving human participants planned sample size: 200 data subjects (100 twin pairs) methodology: a) identification of twin pairs where one or both have inflammatory bowel disease via: 1. ibd nixon twin and multiplex registry. 2. advertising for twin pairs via bsg website and newsletters/patient support groups/social media sites/clinic posters. 3. identification by study sites b) obtaining formal written consent c) collection of blood, stool and urine. d) the following analysis will be carried out: * epigenetics (blood) dna extraction and subsequent methylation analysis and bisulphate conversion with 450 illumina beadchip assay * functional immunology (blood) - flow cytometry of cd3, cd4 and cd8 cells. (london twin pairs discordant for crohn's disease) * 16s rrna gene sequencing (stool) - of bacterial dna * metabolomic profiling (urine and stool) - using nuclear magnetic resonance (nmr) and mass spectrometry e) collection of dietary history information for the previous 72hr period study duration: 2 years (single visit).

Eligibility criteria:
inclusion criteria: * monozygotic twins discordant for ibd * monozygotic twins concordant for ibd * dizygotic twins discordant for ibd * dizygotic twins concordant for ibd * healthy controls exclusion criteria: * \<18 years old * antibiotics within past 3 months of sample collection * unable to give informed consent

Keywords: twins ibd uc cd
pro-thrombotic status in patients with sars-cov-2 infection

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2

Summary: the present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (sars) due to coronavirus 19 (sars-cov-2) infection and moderate-severe respiratory failure the patterns and changes in platelet reactivity, thrombotic status and endothelial function. the observed patterns and changes will be related with inflammatory status, myocardial injury and outcomes

preliminary evidences suggested that patients with sars-cov-2 infection and concomitant presence of cardiovascular risk factors (i.e. arterial hypertension) and/or cardiovascular history (i.e. prior myocardial infarction) are at poor prognosis. the first reports from china suggested in patients with sars-cov-2 infection a heightened inflammatory burden associated with significant changes in coagulative status (i.e. low platelet count, increased d-dimer) and dysfunction of micro-vessels in pulmonary circulation. no data are available about patterns and changes in platelet reactivity, activation of coagulation factors and endothelial function during sars-cov-2 infection. the present study is ideated to fill this gap. patients with moderate to severe respiratory failure due to sars-cov-2 infection will be enrolled. one blood sample will be obtained from each patient at the early, mid and late stage of disease. several markers of platelet, coagulation and endothelial function will be related with laboratory, clinical, electrocardiographic, imaging (transthoracic echocardiogram, pulmonary ultrasonography, computed tomography) and outcome data. to better describe typical patterns of disease regarding inflammation, platelet function and coagulation alteration, data from cases will be compared with control groups negative for sars-cov-2 infection, but with st-segment elevation myocardial infarction or moderate-severe respiratory failure due to other agents.

Eligibility criteria:
inclusion criteria: * diagnosis of moderate-severe respiratory failure (pao2/fio2 \<200) * diagnosis of sars-cov-2 infection + one of the following 1. invasive mechanical ventilation (cohort a) 2. non invasive mechanical ventilation (cohort b) 3. only oxygen support exclusion criteria: * previous chronic use of p2y12 inhibitors * need for chronic oral anti-coagulation therapy * know disorder of coagulation or platelet function
a study of tq-b3525 tablet in the treatment of relapsed / refractory mantle cell lymphoma (mcl)

Conditions: Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Summary: this is a study to evaluate the safety and efficacy of tq-b3525 tablets in patients with relapsed / refractory mantle cell lymphoma (mcl).


Eligibility criteria:
inclusion criteria: * 1. understood and signed an informed consent form; 2. eastern cooperative oncology group (ecog) performance status score of 0 to 2; life expectancy ≥ 3 months; 3. relapsed / refractory mcl; 4. has received at least one-line and less than four lines of previous treatment, the latest treatment confirmed no objective response, or disease progress after treatment; 5. has at least one measurable lesion; 6. adequate organ system function; 7. male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；no pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration. exclusion criteria: * 1. has central nervous system violation; 2. has received other pi3k inhibitors; 3. has diagnosed and/or treated additional malignancy within 3 years prior to the first administration; 4. has history of interstitial lung disease; 5. has a history of immunodeficiency diseases; 6. has multiple factors affecting oral medication; 7. has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1; 8. has received systemic steroid treatment within 7 days before the first administration; 9. has received other systemic anti-tumor medications within 4 weeks before the first administration, or still within the 5 half-life of the medication, which occurs first; 10. has palliative radiation therapy within 4 weeks before the first administration; 11. has active infections within 4 weeks before the first administration; 12. has received surgery, or unhealed wounds within 4 weeks before the first administration; 13. has a history of autologous hematopoietic stem cell transplant within 6 months or allogeneic hematopoietic stem cell transplant; 14. qtcf \> 480ms, lvef \ 1.0 g in 24 hours within 7 days; 16. has active hepatitis b or c; 17. has psychotropic substances abuse or a mental disorder; 18. has other conditions that make it inappropriate for the patient to be enrolled based on investigator's opinion.
study for obtaining mature oocytes by in vitro maturation in oocyte-donor women

Conditions: Female Infertility

Summary: in vitro maturation (ivm) is a technique for obtaining potentially fertilizable oocytes from immature oocytes. an oocyte must be mature both nuclearly and cytoplasmically in order to be competent in the reproductive process. nuclear maturation involves an oocyte in metaphase ii stage and is easily evaluated for its morphology. however, cytoplasmic maturation can only be evaluated by in vitro fertilization of that oocyte a mature nuclear and cytoplasmic oocyte is one capable of producing a viable embryo. this study aims to fine-tune the in vitro maturation (ivm) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase ii stage. in addition, an artificial oocyte activation (aoa) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos. the aim of this study is to evaluate the response to the strategy stimulation with highly purified human menopausal gonadotropin (hmg-hp) administered for three days, in association with a standard methodology of in vitro oocyte maturation (ivm), to be performed on oocyte donors. the correct functioning of this ivm technique would mean a reduction in the costs of ovarian stimulation treatments, as lower doses and shorter stimulation times are required, which implies lower risks for women derived from the medication and less stress for them.


Eligibility criteria:
inclusion criteria: * woman aged 18-35 years who have belonged to the egg donation program. * donors who agree to participate in the pre-trial report and sign informed consent. * good previous documented response to ovarian stimulation (at least 10 oocytes total and/or 8 mii). * donors with at least one previous cycle of donation, in which all the oocytes obtained were fertilized in fresh * patients who come to their last cycle of donation allowed by law * no personal or family medical disorders history. * body mass index between 18-28 kg/m2 * normal uterus and ovaries, without organic pathology * non-polycystic-looking ovaries * antral follicle count (afc) \> 12 from both ovaries on day 2-3 of the menstrual cycle. * normal karyotype * negative values of infectious diseases (hepatitis b virus, hepatitis c virus, human immunodeficiency virus and syphilis) * analytical with cbc, hemostasis and biochemistry with parameters within normality exclusion criteria: * any systemic or metabolic disorder that counterindicates the use of gonadotrophins. * any medical condition involving non-inclusion in the oocyte donation program * who are taking hormonal contraceptives in the last 3 months * severe male factor (semen \< 3 million)

Keywords: oocyte activation in vitro maturation oocyte retrieval donnor hmg-hp
disability, perceived social support and quality of life in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the world health organization international classification of functioning, disability and health has shown that the environment can play a major role in patients' disability, and hence in their quality of life. this study considers social dimensions of quality of life, particularly family as well as social and professional networks.


Eligibility criteria:
inclusion criteria: * multiples sclerosis, according to mcdonald's criteria exclusion criteria: * lack of french language proficiency * severe cognitive impairment * severe aphasia * substance addiction * psychiatric troubles (except for treated major depression) * other severe neurologic or somatic disease * pregnant or breast feeding patient
prostate cancer imaging in early detection (imagined trial)

Conditions: Prostate Cancer

Summary: the researchers hope to learn if specific types of mri software and techniques can help improve early prostate cancer detection at time of a mri-guided prostate biopsy.

a phase 2 prospective, interventional, non-randomized clinical trial design to investigate whether restricted spectrum maps (rsm) attained from rsi-mri (on-q prostate) improves pi-rads accuracy compared to pi-rads alone for the detection of clinically significant prostate cancer. patients who have agreed to undergo an mri and subsequent prostate needle biopsy will be approached to participate in the trial. the aims of the study are as follows: goal 1. validate rsi-mri imaging biomarker performance using a prospective clinical trial. goal 2. calibrate the rsm values across different mri scanner manufacturers. goal 3. translate rsi using a net clinical benefit model.

Eligibility criteria:
inclusion criteria: * selected to undergo an mri-fusion prostate needle biopsy of the prostate. * able to provide informed consent exclusion criteria: * prior diagnosis of prostate cancer (grade group \>1) * metastatic prostate cancer * prior prostate cancer treatment * contraindication to prostate biopsy (e.g., on anticoagulation that cannot be safely discontinued) * inability to undergo mri (e.g., too large to be accommodated in a scanner or with an implant incompatible with mri). * bilateral hip replacement * unable to provide informed consent.

Keywords: detection of prostate cancer software application
clinical and microbiologic outcomes of apdt in the non-surgical treatment of implant inflammation

Conditions: DENT IMPLANTS; LASER

Summary: the purpose of this study is to compare clinical outcomes (change in bleeding sites (bop) and probing depth reduction (ppd) after mechanical debridement of implant surfaces at sites exhibiting plaque induced inflammation with or without adjunctive antimicrobial photodynamic therapy (apdt) and assess the microbiologic profile of plaque samples before and after treatment with or without apdt samples.


Eligibility criteria:
inclusion criteria: * at least one implant with peri-implant inflammation that requires non-surgical treatment. * peri-implant diseases included are peri-implant mucositis and peri-implantitis criteria for diagnosis of peri-implant mucositis or peri-implantitis: 1. red, swollen gingival tissues surrounding the implant 2. presence of bleeding and/or suppuration on gentle probing around the implant 3. increased probing depth compared to probing depth after restoration of the implant (greater than 2mm increase in probing depth) 4. may or may not have progressive bone loss in relation to radiographic bone levels assessed either 1 year following restoration of the implant or ≥3mm of radiographic bone loss from the implant platform -systemically healthy or with controlled common systemic conditions, such as hypertension, that will not affect wound healing. exclusion criteria: * current heavy smokers (\>10 cigarettes/day) * have diabetes or other systemic diseases that may comprise healing * take antibiotics within 3 months before the procedure

Keywords: dental implants laser antimicrobial photodynamic therapy low level laser therapy peri-implant mucositis peri-implantitis